Prostate-specific membrane antigen as a marker of pancreatic cancer cells
The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.
KeywordsProstate-specific membrane antigen Pancreatic cancer Marker
Prostate-specific membrane antigen
Pancreatic ductal adenocarcinoma
National Natural Science Foundation of China (Grant Nos. 81302082, 81272685, 31301151, 81172355); Doctoral Fund of Ministry of Education of China (Grant No. 20101202110002); Key program of Natural Science Foundation of Tianjin (Grant Nos. 09JCZDJC17100, 11JCZDJC18400); major anticancer Technologies R&D Program of Tianjin (Grant No. 12ZCDZSY16700); project of Tianjin Educational Commission (Grant No. 20100123).
Conflict of interest
The authors have no conflict of interest.